News

  • Jul 30, 2018

    NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD) (Read more)

  • May 7, 2018

    Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018

  • Apr 16, 2018

    Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.

  • Jan 17, 2018

    Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by BIOCODEX Oy in Finland (Read more)

  • Dec 19, 2017

    Circadin is celebrating 10 years in market!

  • Oct 15, 2017

    Positive Phase III Results for Neurim Pharmaceuticals’ Pediatric Prolonged-Release Melatonin for Insomnia in Children with Autism Spectrum Disorder (ASD) Presented at the World Sleep Congress in Prague (Read more)

  • Sep 25, 2017

    Neurim Pharmaceuticals’ New Paediatric Prolonged-Release Melatonin (“PedPRM”) to Be Marketed by Flynn Pharma in UK and Ireland (Read more)

  • Sep 24, 2017

    Positive Results of Pivotal Phase III Study of Pediatric Prolonged-Release Melatonin (PedPRM) for Insomnia in Children with Autism Spectrum Disorder (ASD) to be Presented at the World Sleep Congress in Prague on October 9th

  • Jul 3, 2017

    Circadin® 2mg (prolonged-release melatonin) is now funded for insomnia in children and adolescents with Neurodevelopmental Disorders in New Zealand

  • Jun 25, 2017

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Argentina

  • Mar 29, 2017

    Neurim Pharmaceuticals Grants Exeltis Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Spain (Read more)

  • Mar 13, 2017

    Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Biocodex in France (Read more)

  • Dec 6, 2016

    Neurim Pharmaceuticals Paediatric Prolonged-Release Melatonin (“PedPRM”) to be Marketed by Kuhnil Pharmaceutical in South Korea (Read more)

  • Nov 16, 2016

    Neurim Pharmaceuticals Grants Aspen Australia Marketing Rights for Paediatric Prolonged-Release Melatonin (“PedPRM”) in Australia and New Zealand (Read more)

  • Nov 2, 2016

    Neurim Pharmaceuticals Announces Positive Top-Line Results from Pivotal Phase III Trial of Paediatric Prolonged-Release Melatonin (“PedPRM”) for Sleep Disturbances in Children with Autism Spectrum Disorders (ASD) (Read more)

  • Oct 5, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Honduras

  • Sep 28, 2016

    Neurim Pharmaceuticals announces first patients’ enrollments in ReCOGNITION – phase II clinical trial of Piromelatine for mild Alzheimer’s disease (Read more)

  • Aug 2, 2016

    Circadin® receives marketing authorization in Honduras

  • Jun 21, 2016

    Circadin® is now reimbursed under a Temporary Recommendation for Use (RTU) in France for Children with Neurodevelopmental Disorders (Read more)

  • Mar 3, 2016

    Circadin® 2mg (prolonged-release melatonin) is now commercially available in Peru

  • Text size: A A A
  • Circadin
  • Recent news

    • NEURIM PHARMACEUTICALS RECEIVES POSITIVE CHMP OPINION FOR SLENYTO® (PEDIATRIC PROLONGED-RELEASE MELATONIN) FOR THE TREATMENT OF INSOMNIA IN CHILDREN WITH AUTISM SPECTRUM DISORDER (ASD)
    • Neurim Pharmaceuticals attends the INSAR Congress in Rotterdam, The Netherlands, May 9-11, 2018
    • Neurim sponsors a Satellite Symposium “Navigating through the Insomnia Roadmap in Children with ASD” at IPSA 2018, Paris, France.
  • Partners

    Partners